Michael H. MayCEO, Centre for Commercialization of Regenerative Medicine (CCRM)
Michael May is currently the Chief Executive Officer of the Centre for
Commercialization of Regenerative Medicine (CCRM) a Canadian, federally
incorporated, not-for-profit organization dedicated to supporting the
development of foundational technologies that accelerate the
commercialization of stem cell – and biomaterials – based technologies.
Prior to CCRM, Michael was the president, and co-founder of Rimon
Therapeutics Ltd., a Toronto-based regenerative medicine company
developing novel medical polymers that possess drug-like activity.
Dr. May completed his PhD in Chemical Engineering at the University of Toronto in
1998 as an NSERC Scholar and was awarded the Martin Walmsley
Fellowship for Technological Entrepreneurship in recognition of company
creation from academic discovery.
Michael sits on a number of boards and advisory committees including: MaRS Innovation, 20/20 Vision, a centre of excellence for biomaterials in ophthalmology, the Biozone and Bioproducts + Enzymes from Environmental Metagenomes Commercialization Committee and the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto.